Vanguard ESG Developed Europe All Cap UCITS ETF (LON:V3EL)
London · Delayed Price · Currency is GBP 5.30
0.00 (-0.05%)
At close: Aug 18, 2025, 4:30 PM BST
-0.05% (1Y)
| Assets | 24.89M |
| Expense Ratio | 0.12% |
| PE Ratio | 16.58 |
| Dividend (ttm) | 0.15 |
| Dividend Yield | 2.79% |
| Ex-Dividend Date | Jun 19, 2025 |
| Payout Frequency | Quarterly |
| Payout Ratio | 46.35% |
| 1-Year Return | +10.06% |
| Volume | 4,849 |
| Open | 5.29 |
| Previous Close | 5.30 |
| Day's Range | 5.28 - 5.31 |
| 52-Week Low | 4.44 |
| 52-Week High | 5.38 |
| Beta | n/a |
| Holdings | 989 |
| Inception Date | Aug 16, 2022 |
About V3EL
V3EL.AS was created on 2022-08-16 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. This Fund seeks to track the performance of the Index.
Asset Class Equity
Category Total Market
Stock Exchange London Stock Exchange
Ticker Symbol V3EL
Provider Vanguard
Index Tracked FTSE Developed Europe All Cap Choice Index - EUR - Benchmark TR Net
Performance
V3EL had a total return of 10.06% in the past year, including dividends. Since the fund's inception, the average annual return has been 11.09%.
Top 10 Holdings
22.94% of assets| Name | Symbol | Weight |
|---|---|---|
| ASML Holding N.V. | ASML | 3.28% |
| SAP SE | SAP | 3.27% |
| Nestlé S.A. | NESN | 2.63% |
| Roche Holding AG | ROG | 2.39% |
| Novartis AG | NOVN | 2.37% |
| Novo Nordisk A/S | NOVO.B | 2.31% |
| AstraZeneca PLC | AZN | 2.18% |
| Allianz SE | ALV | 1.64% |
| Unilever PLC | ULVR | 1.56% |
| Banco Santander, S.A. | SAN | 1.31% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Jun 19, 2025 | £0.09928 | Jul 2, 2025 |
| Mar 20, 2025 | £0.01714 | Apr 2, 2025 |
| Dec 12, 2024 | £0.01623 | Dec 27, 2024 |
| Sep 12, 2024 | £0.0155 | Sep 25, 2024 |
| Jun 13, 2024 | £0.08911 | Jun 26, 2024 |
| Mar 14, 2024 | £0.01508 | Mar 27, 2024 |